GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (NAS:GHRS) » Definitions » Short-Term Debt & Capital Lease Obligation

GHRS (GH Research) Short-Term Debt & Capital Lease Obligation : $0.34 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is GH Research Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. GH Research's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.34 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. GH Research's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.32 Mil.


GH Research Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for GH Research's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GH Research Short-Term Debt & Capital Lease Obligation Chart

GH Research Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial - - - 0.34 0.26

GH Research Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Short-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.26 0.28 0.26 0.34

GH Research Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


GH Research Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of GH Research's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


GH Research Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (NAS:GHRS) » Definitions » Short-Term Debt & Capital Lease Obligation
Traded in Other Exchanges
Address
Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.